Document is current
Any future updates will be listed below
-
Authors
Dillon, Magnus T. https://orcid.org/0000-0001-5136-5227
Patin, Emmanuel C. https://orcid.org/0000-0001-5390-5733
Mohammed, Kabir
Guevara, Jeane
Smith, Simon A. https://orcid.org/0000-0002-3591-3016
Dean, Emma https://orcid.org/0000-0001-9956-257X
Soliman, Heba
Nenclares, Pablo https://orcid.org/0000-0002-1750-3179
Ryugenji, Motoko
Northcote, Davina
Shah, Neel
Grove, Lorna
Lord, Christopher J. https://orcid.org/0000-0002-3226-0515
Pettit, Stephen
Tall, Matt
Swales, Karen E. https://orcid.org/0000-0002-6572-1293
Banerji, Udai https://orcid.org/0000-0003-1503-3123
Melcher, Alan A. https://orcid.org/0000-0002-2042-3380
Saunders, Mark
Forster, Martin D.
Harrington, Kevin J. https://orcid.org/0000-0002-6014-348X
-
Funding
Funding for this research was provided by:
Cancer Research UK (C7224/A23275; CRUKD/14/007; UK C347/A18077; C309/A25144; CTRQQR-2021\100009)
Rosetrees Trust
AstraZeneca
DH | National Institute for Health Research (NIHR202438)
CRIS Cancer Foundation Experimental Cancer Medicine Centre Paul and Kathy Beaumont
- License Information
-
More Information
Article History
Received: 31 October 2024
Accepted: 15 July 2025
First Online: 1 August 2025
Competing interests
: K.E.S is an employee of The Institute of Cancer Research, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1, and HSF1 inhibitors. C.J.L. makes the following disclosures: receives and/or has received research funding from: AstraZeneca, Merck KGaA, Artios, Neophore. Received consultancy, SAB membership or honoraria payments from: Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, Neophore, Glaxo Smith Kline, Dawn Bioventures. Has stock in: Tango, Ovibio, Hysplex, Tesselate. U.B. reports research funding, honoraria and advisory board membership for Chugai Pharmaceutical, Verastem Inc., and Carrick Therapeutics K.J.H. reports honoraria (inst.): ALX Pharma, Arch Oncology, AstraZeneca, Bicara Therapeutics, BMS, Boehringer Ingelheim, Codiak Biosciences, F-Star Therapeutics, Inzen Therapeutics, Merck Serono, Merus, MSD, Oncolys Biopharma, Pfizer, Replimune, VacV Biotherapeutics; Consulting or Advisory Role (inst.): Arch Oncology, AstraZeneca, BMS, Boehringer Ingelheim, Inzen Therapeutics, Merck Serono, MSD, Oncolys BioPharma, Replimune; Speakers’ Bureau (inst.): BMS, Merck Serono, MSD; Research Funding (inst.): AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Replimune. E.D., S.A.S., N.S. are employees of AstraZeneca with stock ownership. The remaining authors declare no competing interests.
